Capricor Therapeutics (CAPR) Set to Release Earnings on Monday

Key Points

• Capricor Therapeutics is expected to report Q3 2026 earnings after the market closes on Monday, November 9, with analysts forecasting a loss of $0.1278 per share and revenue of $41.71 million.
• The company previously reported a larger-than-expected Q2 loss of $0.70 per share, versus consensus estimates of $0.59, and analysts project full-year and next-year losses of $1.71 and $1.19 per share, respectively.
• CAPR shares opened at $6.84, while Wall Street’s overall rating is Hold; four analysts recommend Buy, six Hold, and one Sell, with an average price target of $30.25.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Capricor Therapeutics to announce earnings of ($0.1278) per share and revenue of $41.71 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.11). On average, analysts expect Capricor Therapeutics to post ($1.71) EPS for the current fiscal year and ($1.19) EPS for the next fiscal year.

Capricor Therapeutics Stock Up 7.2%

CAPR stock opened at $6.84 on Monday. The business has a 50-day simple moving average of $8.06 and a 200 day simple moving average of $20.60. The company has a market cap of $397.79 million, a PE ratio of -2.78 and a beta of 0.61. Capricor Therapeutics has a 52 week low of $2.96 and a 52 week high of $40.37.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CAPR. Maxim Group lowered Capricor Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, July 30th. Alliance Global Partners cut Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 target price on the stock. in a research report on Tuesday, July 28th. JonesTrading lowered shares of Capricor Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, July 31st. LADENBURG THALM/SH SH lowered Capricor Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, July 30th. Finally, Piper Sandler upgraded shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, September 1st. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $30.25.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company's research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor's lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.